ClinicalTrials.gg
CompletedNCT05324293Updated Sep 19, 2024

To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

A Phase 1 interventional study of HMI-115 in Androgenetic Alopecia, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Alopecia with a site in Australia — 3 open to participants now, 4 under way, 1 of them phase 3. Alopecia · Australia.

Enrollment
14th of 14
16 · median 131
Started
2022
with 2 others
Phase 1
3 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
1 of 16
Hope Medicine (Nanjing) Co., Ltd

Among the 16 studies in Alopecia with a site in Australia, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1, and was the 9th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 16 studies in Alopecia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alopecia with a site in Australia, or all of them as a file.
02

Study summary

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Male and Female subjects, between 18 and 65 years of , inclusive, at the time of signing informed consent.
  3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales 3v, 4 and 5. Female subjects who meet Sinclair scales 2-4.

Exclusion criteria

Exclusion Criteria:

  1. Subject with clinical diagnosis of non-AGA
  2. Subject with abnormal skin or scalp findings which could interfere study assessment
  3. Subject has used therapies associated with hair growth or may affect PRL levels, within defined time window before Screening
  4. Subject with history of anterior pituitary, posterior pituitary, or hypothalamic dysfunction
  5. Subject has clinically significantly abnormal laboratory tests at Screening
  6. Known to any of the IMP ingredients
  7. Any other conditions in the investigator's opinion that prevent the subject from participating
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    HMI-115 240mg

    Drug: HMI-115

Interventions

  • Once Every 2 weeks, subcutaneously injection

06

What researchers measure

Primary outcomes

  1. TAHC(target area hair count) of non-vellus

    Change in target area hair count (TAHC) of non-vellus from baseline to Week 24 in male and female AGA subjects, respectively.

    Time frame: From baseline to Week 24

Secondary outcomes

  1. TAHC of non-vellus

    Change in TAHC of non-vellus from baseline to Week 6, 12, 18, and 36 in male and female, respectively.

    Time frame: From baseline to Week 6, 12, 18, and 36

  2. TAHW(target area hair width) of non-vellus hair

    Change in target area hair width (TAHW) of non-vellus hair from baseline to Week 6, 12, 18, 24, and 36 in male and female, respectively.

    Time frame: From baseline to Week 6, 12, 18, 24, and 36

  3. Investigator Global Assessment (IGA)

    IGA at Week 6, 12, 18, 24, and 36 in male and female, respectively.

    Time frame: Week 6, 12, 18, 24, and 36

  4. Subject self-Assessment (SSA)

    SSA at Week 6, 12, 18, 24, and 36 in male and female, respectively.

    Time frame: Week 6, 12, 18, 24, and 36

  5. Hair growth questionnaire assessment (HGQA)

    HGQA at Week 6, 12, 18, 24, and 36 in male and female, respectively.

    Time frame: Week 6, 12, 18, 24, and 36

07

Study locations

1 site
  • Dr Rodney Sinclair Pty Ltd, trading as Sinclair Dermatology
    Melbourne E., Victoria, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2023, 16 months.

Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 12, 2022
StartActual
May 11, 2022
Primary completionActual
Sep 11, 2023
CompletionActual
Sep 11, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05324293
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
May 11, 2022
Primary completion
Sep 11, 2023
Completion
Sep 11, 2023
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMI-115

Start the discussion